Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Otsuka Holdings Co ( (JP:4578) ) is now available.
Otsuka Holdings Co., Ltd. announced that the FDA has accepted the Biologics License Application for sibeprenlimab, a monoclonal antibody for treating IgA nephropathy, with a priority review. This development could significantly impact Otsuka’s positioning in the nephrology market by offering a new treatment option that allows patients to self-administer the medication, potentially improving convenience and clinical outcomes for those with this chronic kidney disease.
The most recent analyst rating on (JP:4578) stock is a Buy with a Yen10400.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Pharmaceutical Co., Ltd. is a comprehensive healthcare company that focuses on enhancing individual well-being through medical-related treatments and diagnostics for both physical and mental health, as well as nutraceuticals for daily health maintenance and improvement. Their products and services are grounded in scientific evidence.
YTD Price Performance: -22.67%
Average Trading Volume: 1,309,352
Technical Sentiment Signal: Hold
Current Market Cap: Yen3508.2B
Find detailed analytics on 4578 stock on TipRanks’ Stock Analysis page.